| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2774752 | Endocrinología y Nutrición | 2006 | 5 Pages |
Abstract
Bexarotene treatment in patients with CTCL produces endocrinemetabolic alterations such as central hypothyroidism and mixed dyslipidemia, which usually require treatment with additional doses of levothyroxine and lipidlowering agents. These changes are reversible after discontinuing the drug.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Amparo Marco, Cristina Familiar, Julia Sastre, Bárbara Cánovas, Almudena Vicente, José López,